Rodenticide Toxicosis

Rodenticide toxicosis refers to the clinical syndrome resulting from the accidental or malicious ingestion of rodenticides, which are chemical agents designed to kill rodents. These compounds are commonly used in and around human dwellings, agricultural settings, and commercial properties, posing a significant risk to domestic animals, particularly dogs and cats. Rodenticides are broadly classified into several groups based on their active ingredient and mechanism of action: anticoagulant rodenticides (first-generation and second-generation), bromethalin, cholecalciferol (vitamin D3), zinc phosphide, and strychnine. Each class produces a distinct clinical syndrome, ranging from coagulopathy and hemorrhage to neurotoxicity, hypercalcemia, and metabolic acidosis. The severity and onset of clinical signs depend on the specific toxin, the dose ingested, the species affected, and the timeliness of intervention. Rodenticide toxicosis is a medical emergency that requires prompt recognition, decontamination, and aggressive supportive care to prevent morbidity and mortality.

The primary causative agents are the active ingredients in rodenticide formulations. Anticoagulant rodenticides, such as warfarin, brodifacoum, bromadiolone, and diphacinone, inhibit vitamin K epoxide reductase, leading to depletion of vitamin K-dependent clotting factors (II, VII, IX, X). Bromethalin is a neurotoxic agent that uncouples oxidative phosphorylation in the central nervous system, causing cerebral edema and increased intracranial pressure. Cholecalciferol (vitamin D3) causes hypercalcemia and hyperphosphatemia, leading to acute kidney injury and soft tissue mineralization. Zinc phosphide releases phosphine gas in the acidic environment of the stomach, causing severe gastrointestinal irritation and systemic toxicity. Strychnine acts as a competitive antagonist at glycine receptors in the spinal cord, resulting in uncontrolled muscle spasms and seizures. Other less common rodenticides include sodium fluoroacetate (compound 1080), which disrupts the Krebs cycle, and thallium, which is now largely banned. The toxic potential of these agents is influenced by the concentration of the active ingredient, the bait matrix (e.g., grain, wax blocks, pellets), and the palatability to pets.

Rodenticide toxicosis is one of the most common toxicities reported in small animal practice, with dogs being disproportionately affected due to their indiscriminate eating habits. Cats are less commonly affected but can be exposed through ingestion of poisoned rodents (secondary poisoning) or direct consumption of bait. There is no breed or sex predilection, but young animals are at higher risk due to curiosity and exploratory behavior. The incidence is higher in rural and suburban areas where rodent control is more frequent, and it often peaks in the fall and spring when rodent populations are managed. Anticoagulant rodenticides are the most frequently implicated, accounting for the majority of cases, followed by bromethalin and cholecalciferol. The widespread availability of these products over-the-counter increases the risk of accidental exposure. Secondary poisoning in dogs and cats that ingest poisoned rodents is rare but possible, especially with anticoagulants, though the dose is usually sublethal.

The pathophysiology of rodenticide toxicosis varies by class. Anticoagulant rodenticides inhibit the enzyme vitamin K epoxide reductase in the liver, preventing the recycling of vitamin K and the gamma-carboxylation of clotting factors II, VII, IX, and X. This results in a functional deficiency of these factors, leading to coagulopathy and spontaneous hemorrhage. The onset of clinical signs is delayed by 24-72 hours, as existing clotting factors are depleted. Bromethalin is a potent uncoupler of oxidative phosphorylation in the central nervous system, leading to depletion of ATP, failure of the sodium-potassium pump, and subsequent cellular swelling and cerebral edema. Clinical signs include ataxia, seizures, and coma, which can appear within hours to days. Cholecalciferol is metabolized to active vitamin D, which increases intestinal absorption of calcium and phosphorus and promotes bone resorption, leading to hypercalcemia and hyperphosphatemia. This results in acute kidney injury due to vasoconstriction, calcification of renal tubules, and polyuria, followed by oliguria or anuria. Zinc phosphide, when exposed to gastric acid, releases phosphine gas, which is directly toxic to cells, causing severe gastrointestinal necrosis, pulmonary edema, and hepatic and renal damage. Strychnine competitively blocks glycine receptors in the spinal cord, leading to disinhibition of motor neurons and severe muscle spasms, which can cause respiratory failure and hyperthermia.

Intrinsic risk factors include species (dogs are more likely to ingest rodenticides), age (young animals are more curious and less discriminating), and individual metabolic differences. Extrinsic factors include the accessibility of rodenticide baits, improper storage, and the use of bait stations that are not tamper-proof. Concurrent diseases, such as hepatic dysfunction, can exacerbate the effects of anticoagulant rodenticides due to impaired clotting factor synthesis. Animals with pre-existing renal disease are more susceptible to the nephrotoxic effects of cholecalciferol. The presence of other toxins or medications that affect coagulation, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or salicylates, can increase the risk of bleeding. Environmental factors, such as the placement of baits in areas accessible to pets, and the lack of owner awareness about the dangers of rodenticides, are significant contributors.

Clinical signs depend on the type of rodenticide and the time since exposure. For anticoagulant rodenticides, signs are typically delayed by 24-72 hours and include lethargy, weakness, pale mucous membranes, ecchymoses, petechiae, epistaxis, hematuria, melena, hematemesis, hemoptysis, and bleeding from the gingiva. In severe cases, bleeding into the thoracic or abdominal cavities can cause dyspnea, abdominal distension, and collapse. Neurological signs may occur if bleeding occurs in the central nervous system. Bromethalin toxicosis presents with acute onset of ataxia, tremors, seizures, hyperexcitability, and coma, often within 2-24 hours of ingestion. Cholecalciferol toxicosis initially causes vomiting, depression, and anorexia, followed by polyuria, polydipsia, and signs of acute kidney injury such as dehydration, oliguria, and uremic breath. Zinc phosphide ingestion causes severe vomiting, abdominal pain, diarrhea, and signs of shock, with respiratory distress due to pulmonary edema. Strychnine poisoning is characterized by severe muscle spasms, opisthotonos, and seizures, which can be triggered by any external stimulus.

Differential diagnoses for anticoagulant rodenticide toxicosis include other causes of coagulopathy such as disseminated intravascular coagulation (DIC), immune-mediated thrombocytopenia, von Willebrand disease, hemophilia, liver failure, and snake envenomation. For bromethalin toxicosis, differentials include other causes of acute neurological signs such as head trauma, meningitis, encephalitis, and intoxication with other neurotoxins (e.g., metaldehyde, strychnine, organophosphates). Cholecalciferol toxicosis should be differentiated from other causes of hypercalcemia, including malignancy, primary hyperparathyroidism, and chronic renal failure. Zinc phosphide poisoning may mimic other causes of severe gastroenteritis and shock, such as pancreatitis, gastrointestinal foreign body, or sepsis. Strychnine poisoning must be distinguished from other causes of seizures and muscle rigidity, including tetanus, strychnine-like alkaloids, and certain plant toxins.

The diagnostic approach begins with a thorough history, including the possibility of exposure to rodenticides, the type of product, and the time of ingestion. Physical examination should focus on signs of bleeding, neurological abnormalities, and hydration status. For suspected anticoagulant toxicosis, a baseline coagulation profile (prothrombin time, activated partial thromboplastin time) and a complete blood count are essential. If the PT is prolonged, a vitamin K response test can be performed. For bromethalin, diagnosis is often based on history and clinical signs, as there is no specific antemortem test; however, magnetic resonance imaging may reveal cerebral edema. Cholecalciferol toxicosis is diagnosed by measuring serum calcium, phosphorus, and kidney function (creatinine, BUN). Zinc phosphide poisoning is diagnosed based on history and clinical signs, and the presence of a garlic-like odor on the breath. Strychnine poisoning is diagnosed by history and clinical signs, and toxicological analysis of stomach contents or urine can confirm the presence of the toxin. In all cases, if the product is known, the label should be consulted for active ingredients and antidotes.

In anticoagulant rodenticide toxicosis, laboratory findings include prolonged PT and aPTT, thrombocytopenia may be present due to hemorrhage, and anemia may develop secondary to blood loss. Serum biochemistry may show elevated liver enzymes if hepatic hemorrhage occurs. In bromethalin toxicosis, laboratory findings are often unremarkable, but cerebrospinal fluid analysis may show increased protein and pressure. Cholecalciferol toxicosis is characterized by hypercalcemia (total calcium >12 mg/dL), hyperphosphatemia, and elevated BUN and creatinine. Urinalysis may show low urine specific gravity, proteinuria, and casts. Zinc phosphide poisoning may cause metabolic acidosis, elevated liver enzymes, and evidence of renal injury. Strychnine poisoning may cause elevated creatine kinase due to muscle damage, and blood gas analysis may show respiratory acidosis or alkalosis depending on the stage.

Radiography is useful in anticoagulant toxicosis to identify thoracic or abdominal hemorrhage, which may appear as pleural effusion, pulmonary infiltrates, or abdominal fluid. Ultrasonography can detect free fluid in the abdomen and assess organ integrity. In bromethalin toxicosis, MRI of the brain may show diffuse cerebral edema, but this is not always available. Cholecalciferol toxicosis may show mineralization of soft tissues on radiographs, particularly in the kidneys, stomach, and blood vessels. Zinc phosphide poisoning may show gastric dilation and evidence of pulmonary edema on thoracic radiographs. Strychnine poisoning does not have specific imaging findings, but radiographs may be taken to rule out other causes of seizures.

Cytology and histopathology are not typically used for antemortem diagnosis of rodenticide toxicosis, but postmortem examination can reveal characteristic lesions. In anticoagulant toxicosis, gross findings include widespread hemorrhage, and histopathology shows depletion of clotting factors. Bromethalin toxicosis may show spongiosis of the white matter and cerebral edema. Cholecalciferol toxicosis reveals mineralization of the renal tubules, stomach, and blood vessels. Zinc phosphide poisoning causes severe gastric and intestinal necrosis, and histopathology shows cellular degeneration. Strychnine poisoning has no specific histopathological lesions.

Treatment depends on the type of rodenticide and the clinical status of the patient. For anticoagulant toxicosis, the mainstay is vitamin K1 (phytonadione) at a dose of 2.5-5 mg/kg PO or SC, initially, followed by 1.5-2.5 mg/kg PO q12h for 4-6 weeks, depending on the type of anticoagulant. In severe cases with active bleeding, fresh frozen plasma or whole blood transfusion may be necessary. For bromethalin toxicosis, treatment is symptomatic and supportive, including aggressive management of cerebral edema with mannitol (0.5-1 g/kg IV over 20 minutes) and hypertonic saline, anticonvulsants such as diazepam (0.5-1 mg/kg IV) or levetiracetam (20 mg/kg IV), and mechanical ventilation if needed. Cholecalciferol toxicosis requires aggressive fluid therapy with 0.9% sodium chloride, loop diuretics such as furosemide (1-4 mg/kg IV q8h), and corticosteroids such as prednisolone (1-2 mg/kg PO q12h) to reduce intestinal calcium absorption. Calcitonin (4-6 IU/kg SC q8h) may be used in severe hypercalcemia. Zinc phosphide poisoning requires immediate decontamination with gastric lavage and administration of activated charcoal (1-2 g/kg PO), along with supportive care for shock and respiratory distress. Strychnine poisoning is treated with muscle relaxants such as methocarbamol (55-220 mg/kg IV to effect) or diazepam, and the animal should be kept in a quiet, dark environment to minimize stimulation.

The prognosis for rodenticide toxicosis varies widely. With prompt and appropriate treatment, the prognosis for anticoagulant toxicosis is generally good, with a survival rate of over 90% if treated early. However, severe hemorrhage can be fatal. Bromethalin toxicosis has a guarded prognosis, especially if neurological signs are severe, with a mortality rate of up to 50%. Cholecalciferol toxicosis has a fair to guarded prognosis, depending on the degree of renal injury; early treatment can prevent permanent kidney damage. Zinc phosphide poisoning has a poor prognosis if severe, due to the rapid onset of systemic toxicity. Strychnine poisoning has a guarded prognosis, but with aggressive treatment, many animals can recover if they survive the first 24 hours.

Follow-up care depends on the type of rodenticide. For anticoagulant toxicosis, repeat PT should be checked 48-72 hours after starting vitamin K1 therapy, and then periodically during treatment. The dose of vitamin K1 should be adjusted based on PT values, and treatment should be continued for at least 4 weeks for first-generation anticoagulants and 6 weeks for second-generation anticoagulants. After discontinuation, PT should be rechecked 48-72 hours later to ensure it is normal. For bromethalin, neurological function should be monitored, and repeat imaging may be needed. For cholecalciferol, serum calcium and kidney function should be monitored every 24-48 hours until normalized, and then weekly for several weeks. For zinc phosphide and strychnine, supportive care and monitoring of vital signs are essential, and the animal should be observed for 24-72 hours.

Pearls: Always consider rodenticide toxicosis in any animal with unexplained bleeding, neurological signs, or hypercalcemia. Obtain a thorough history, including the type of rodenticide and time of exposure. For anticoagulant toxicosis, vitamin K1 is the antidote, but it must be given for a sufficient duration to prevent recurrence. For bromethalin, early aggressive treatment of cerebral edema is critical. For cholecalciferol, aggressive fluid therapy and management of hypercalcemia are essential to prevent renal failure. Pitfalls: Do not induce vomiting in animals with strychnine poisoning, as it may precipitate seizures. Do not use vitamin K1 alone for anticoagulant toxicosis if the animal is actively bleeding; blood products are needed. Do not underestimate the toxicity of bromethalin, as it has a narrow margin of safety. Do not forget to monitor for secondary complications such as aspiration pneumonia, renal failure, and disseminated intravascular coagulation.

Anticoagulant rodenticide toxicosis: Vitamin K1 (phytonadione) 2.5-5 mg/kg SC initially, followed by 1.5-2.5 mg/kg PO q12h for 4-6 weeks. For active bleeding, fresh frozen plasma (10-20 mL/kg IV) or whole blood (20 mL/kg IV) may be administered. Bromethalin toxicosis: Mannitol 0.5-1 g/kg IV over 20 minutes, repeated as needed; hypertonic saline (7.5%) 3-5 mL/kg IV over 15 minutes; diazepam 0.5-1 mg/kg IV for seizures; levetiracetam 20 mg/kg IV q8h; furosemide 1-2 mg/kg IV q8h for cerebral edema. Cholecalciferol toxicosis: 0.9% sodium chloride IV at 2-3 times maintenance (60-90 mL/kg/day) to promote calciuresis; furosemide 1-4 mg/kg IV q8h; prednisolone 1-2 mg/kg PO q12h; calcitonin 4-6 IU/kg SC q8h; pamidronate 1-2 mg/kg IV over 2 hours in severe cases. Zinc phosphide poisoning: Gastric lavage with sodium bicarbonate (1 mEq/kg IV) to reduce stomach acidity; activated charcoal 1-2 g/kg PO; supportive care with IV fluids, antiemetics (maropitant 1 mg/kg SC q24h), and oxygen therapy. Strychnine poisoning: Methocarbamol 55-220 mg/kg IV to effect; diazepam 0.5-1 mg/kg IV; keep in a quiet, dark environment; supportive care with IV fluids and cooling if hyperthermic.

Evidence-based literature supports the use of vitamin K1 for anticoagulant rodenticide toxicosis, with a recommended duration of treatment based on the half-life of the specific anticoagulant. Studies have shown that second-generation anticoagulants require longer treatment (up to 6 weeks) due to their prolonged half-life. For bromethalin, research indicates that early decontamination and aggressive management of cerebral edema improve outcomes. Cholecalciferol toxicosis studies emphasize the importance of aggressive fluid therapy and the use of bisphosphonates in severe hypercalcemia. Zinc phosphide and strychnine toxicosis are less studied, but case reports and retrospective studies provide guidance on supportive care. The ACVIM consensus statements on coagulopathies and the ASPCA Animal Poison Control Center guidelines are valuable resources for evidence-based recommendations.